Arcturus Therapeutics Holdings INC 8-K filings

Arcturus Therapeutics announced its second quarter 2026 financial results, detailing progress in its ARCT-032 and ARCT-810 drug candidates, and the strategic regaining of global rights to its KOSTAIVE and infectious disease vaccine portfolio.

Arcturus Therapeutics has entered into a strategic collaboration with Thermo Fisher Scientific to advance its investigational mRNA therapy for cystic fibrosis, ARCT-032.

Arcturus Therapeutics stockholders re-elected the board of directors and ratified the appointment of Deloitte as auditor.

Arcturus Therapeutics announced its fourth quarter and fiscal year 2025 financial results, highlighting progress in its rare disease pipeline and an extended cash runway.

Arcturus Therapeutics announced the mutual separation of CFO Andy Sassine and the appointment of Controller Joe Roberts as interim principal financial and accounting officer.

Arcturus Therapeutics announced its third quarter 2025 financial results, highlighted by encouraging cystic fibrosis trial data, strategic cost reductions, and a delay in its U.S. COVID-19 vaccine BLA filing.

Arcturus Therapeutics announced encouraging interim Phase 2 results for its cystic fibrosis therapy ARCT-032 but faced a significant delay and new data requirements for its KOSTAIVE COVID-19 vaccine BLA submission to the FDA.

Meiji Seika Pharma, a partner of Arcturus Therapeutics, has launched a new two-dose vial presentation of KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine targeting the Omicron JN.1 variant XEC, in Japan.

Arcturus Therapeutics' partner Meiji Seika Pharma has received manufacturing and marketing approval in Japan for KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine.

Arcturus Therapeutics reports Q2 2025 financial results with reduced net loss and significant clinical advancements across its mRNA therapeutics and vaccine pipeline.

Arcturus Therapeutics Holdings Inc. announced positive interim Phase 2 results for its mRNA therapeutic candidate ARCT-810, showing significant reduction in glutamine levels and increased ureagenesis in patients with Ornithine Transcarbamylase (OTC) deficiency.

Arcturus Therapeutics Holdings Inc. announced that its stockholders approved all proposals at the 2025 annual meeting, including the re-election of nine directors, advisory approval of executive compensation, and ratification of Deloitte & Touche LLP as independent auditors.

Arcturus Therapeutics reports Q1 2025 financial results, highlights pipeline progress, and announces an extended cash runway into 2028 through strategic prioritization.

Arcturus Therapeutics reports Q4 and full-year 2024 financial results, highlighting progress in rare disease programs and mRNA vaccine development.

Arcturus Therapeutics announced its third quarter 2024 financial results, highlighted by a $25 million milestone achievement from the first sale of KOSTAIVE in Japan and progress in its clinical programs.

Arcturus Therapeutics has released an updated corporate presentation on its website, providing insights into its ongoing activities and future plans.

Arcturus Therapeutics announced its second quarter 2024 financial results, highlighting a significant revenue increase and advancements in its clinical pipeline.

Arcturus Therapeutics has appointed Dr. Moncef Slaoui, former Chief Scientific Advisor for Operation Warp Speed, to its Board of Directors.

Arcturus Therapeutics stockholders approved an increase in the number of shares available under the company's equity incentive plan and elected eight directors at their annual meeting.

Arcturus Therapeutics announced its first quarter 2024 financial results, along with updates on its pipeline progress, including the commercialization of Kostaive and key clinical trial milestones.

Arcturus Therapeutics has dismissed Ernst & Young LLP and appointed Deloitte & Touche LLP as its new independent registered public accounting firm, effective April 5, 2024.

Arcturus Therapeutics' bivalent COVID-19 vaccine, Kostaive, successfully met its primary endpoint in a Phase III clinical trial for booster vaccinations in Japan.

Arcturus Therapeutics has revised its financial results for fiscal year 2023 and the fourth quarter due to non-cash revenue adjustments identified during the year-end audit.

Arcturus Therapeutics announced its fourth quarter and full year 2023 financial results, along with key pipeline advancements, including the anticipated launch of Kostaive in Japan and extended cash runway to Q1 2027.

Arcturus Therapeutics' Senior Vice President of Finance and Corporate Controller, Keith C. Kummerfeld, will resign effective March 15, 2024, with Joseph Roberts promoted to Controller.